Christian Klein, PhDHead Oncology Programs at Roche Innovation Center Zurich
Christian Klein, Distinguished Scientist, is Head of Oncology Programs and Department Head Cancer Immunotherapy Discovery 3 at the Roche Innovation Center Zurich (Roche Pharma Research & Early Development, pRED). Since 06/2019 he also acts as Site Head of RICZ. He specialized in the discovery, engineering, validation and preclinical development of therapeutic (bispecific) antibodies for cancer immunotherapy. During his 18 year tenure at Roche he has made major contributions to the preclinical development and approvals of GAZYVA(RO) (obinutuzumab, GA101), and to the preclinical development of 15 bispecific antibodies, immunocytokines and antibody fusion proteins entering clinical trials. He lead(s) research teams developping Roche’s bispecific antibody technologies e.g. the CrossMab, immunocytokine and T-cell bispecific antibody platforms, and contributed to preclinical research on the IGF-1R mAb teprotumumab (R1507, TEPEZZA), and the MDM2 inhibitor idasanutlin (RG7388). He co-authored >130 publications, contributed to >150 patent applications on cancer therapy, therapeutic/bispecific antibodies and antibody engineering, and is an external lecturer (PD) in biochemistry at the Ludwig-Maximilians University (LMU) in Munich since 2017.